Loading
A UK study testing Elypta's plasma sugar-molecule test for many cancers in heavy smokers taking part in lung screening.
LEVANTIS-0093A (NCT05295017) is an observational study sponsored by Elypta. It validates the plasma free GAGome multi-cancer test using samples and data from the Yorkshire Lung Screening Trial and Yorkshire Kidney Screening Trial.
The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 19 September 2024), with 1,235 participants enrolled, a start on 14 March 2022 and primary completion expected in October 2025.
Shares Elypta GAGome multi-cancer test, Elypta, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Elypta GAGome multi-cancer test, Elypta, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Elypta GAGome multi-cancer test, Elypta, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/